Figure 8
(A) UALCAN and LOGpc-based MTHFD1L prognostic significance in BLCA patients of different cancer stages, races, genders, and ages. (B) UALCAN and LOGpc-based MTHFD1L prognostic significance in HNSC patients of different cancer stages, races, genders, and ages. (C) UALCAN and LOGpc-based MTHFD1L prognostic significance in KIRP patients of different cancer stages, races, genders, and ages. (D) UALCAN and LOGpc-based MTHFD1L prognostic significance in LUAD patients of different cancer stages, races, genders, and ages. (E) UALCAN and LOGpc-based MTHFD1L prognostic significance in UCEC patients of different cancer stages, races, genders, and ages. *P<0.05.
UALCAN and LOGpc-based prognostic significance of MTHFD1L overexpression in BLCA, HNSC, KIRP, LUAD, and UCEC patients of different clinicopathological features

(A) UALCAN and LOGpc-based MTHFD1L prognostic significance in BLCA patients of different cancer stages, races, genders, and ages. (B) UALCAN and LOGpc-based MTHFD1L prognostic significance in HNSC patients of different cancer stages, races, genders, and ages. (C) UALCAN and LOGpc-based MTHFD1L prognostic significance in KIRP patients of different cancer stages, races, genders, and ages. (D) UALCAN and LOGpc-based MTHFD1L prognostic significance in LUAD patients of different cancer stages, races, genders, and ages. (E) UALCAN and LOGpc-based MTHFD1L prognostic significance in UCEC patients of different cancer stages, races, genders, and ages. *P<0.05.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.
Accept